Literature DB >> 19221701

[Surgical therapy of abdominal and trunk soft tissue sarcomas].

S Schimmack1, M W Büchler, J Weitz.   

Abstract

Soft tissue sarcomas are rare tumours of mesenchymal cells which can arise in all parts of the body. Sarcomas of the trunk and abdominal cavity are a very heterogeneous group of tumours. This review focuses on retroperitoneal sarcomas, which tend to be asymptomatic for a long time, resulting in an advanced stage at presentation in most patients. Surgical resection is the basis for cure in these patients, possibly combined with radiation. In contrast to extremity sarcomas, the majority of patients with retroperitoneal sarcomas succumb to an isolated local recurrence of the disease. In case of local recurrence or distant metastases, surgical resection should again be contemplated.

Entities:  

Mesh:

Year:  2009        PMID: 19221701     DOI: 10.1007/s00104-008-1596-5

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  35 in total

1.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas.

Authors:  S Leyvraz; S Jelic
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

Review 2.  [Gastrointestinal stromal tumors (GIST). Surgical therapy].

Authors:  M N Wente; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

3.  Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.

Authors:  Robert Krempien; Falk Roeder; Susanne Oertel; Jürgen Weitz; Frank W Hensley; Carmen Timke; Angela Funk; Katja Lindel; Wolfgang Harms; Markus W Buchler; Jürgen Debus; Martina Treiber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

Review 4.  Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement.

Authors:  Matthias H M Schwarzbach; Yura Hormann; Ulf Hinz; Christine Leowardi; Dittmar Böckler; Gunhild Mechtersheimer; Helmut Friess; Markus W Büchler; Jens-R Allenberg
Journal:  J Vasc Surg       Date:  2006-07       Impact factor: 4.268

5.  Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.

Authors:  K G Billingsley; M E Burt; E Jara; R J Ginsberg; J M Woodruff; D H Leung; M F Brennan
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

6.  Influence of biologic factors and anatomic site in completely resected liposarcoma.

Authors:  D C Linehan; J J Lewis; D Leung; M F Brennan
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

7.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.

Authors:  Jürgen Weitz; Christina R Antonescu; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy.

Authors:  R Smith; Y Pak; W Kraybill; J M Kane
Journal:  Eur J Surg Oncol       Date:  2008-02-21       Impact factor: 4.424

9.  Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control.

Authors:  Sylvie Bonvalot; Michel Rivoire; Marine Castaing; Eberhard Stoeckle; Axel Le Cesne; Jean Yves Blay; Agnès Laplanche
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

10.  Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

Authors:  Samuel Singer; Cristina R Antonescu; Elyn Riedel; Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

View more
  2 in total

Review 1.  [Vascular replacement in abdominal tumor surgery].

Authors:  A Mehrabi; P Houben; N Attigah; D Böckler; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

Review 2.  A guide to oncological management of soft tissue tumours of the abdominal wall.

Authors:  K J Williams; A J Hayes
Journal:  Hernia       Date:  2013-09-17       Impact factor: 4.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.